FDA approved an at-home induction option for risankizumab-rzaa in adults with moderate-to-severe Crohn's disease, based on the phase 3 AFFIRM trial.
Feature|Videos|November 19, 2025
The Clarity Gap: The Shift Toward Real-Time, Defensible Decision-Making in Pharma
Author(s)David Edelman, Thrivable
This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss the rising “clarity gap” that is currently putting pharma leaders under pressure.
Advertisement
Advertisement
This episode introduces David Edelman, Founder and CEO of Thrivable, who joins Pharmaceutical Executive to break down why executives are under more scrutiny than ever, why six-week-old reports and social chatter no longer cut it, and how AI-powered, real-time patient intelligence is transforming leadership from reactive guessing to confident, defensible decision-making.
Related to this article
Treasury proposes adding biotechnology to its Outbound Investment Security Program, a pharma funding roundup covers Gilead’s $1.275 billion acquisition of an oral IL-23R inhibitor from PepStar and Zymeworks’ licensing deal with Roche, and Incubate’s John Stanford on why MFN is an offer pharma can’t refuse.
Dave Maraldo, Ph.D., president of manufacturing at Merck, explains how flexible capacity, earlier input from manufacturing in R&D, and digital tools are helping the organization keep up with a faster, more varied portfolio.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Gilead agrees to acquire an oral IL-23R inhibitor from PepStar, while Zymeworks licenses its DLL3-targeting T cell engager ZW209 to Roche.
Incubate’s John Stanford on why MFN is voluntary in name only — and why the moonshot is the first casualty of drug pricing pressure.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
Advertisement
Advertisement